Search research articles
Contact Us
Filters
Showing results (571-580 of 621) with videos related to
Page
of 63
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
August 12, 2015
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch, Cynthia Tallant, Oleg Fedorov, et al.
Blood
|
September 20, 2017
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2007
Aminopyrrolidineamide inhibitors of site-1 protease
Bruce A Hay, Barbara Abrams, Allice Y Zumbrunn, et al.
Blood Advances
|
November 20, 2019
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
Joshua A Hill, Elizabeth M Krantz, Kevin A Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 26, 2008
Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals
Julie L Hawkins, Michael D Robbins, Laurie C Warren, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2004
2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors
Stephen M Courtney, Philip A Hay, Richard T Buck, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 28, 2009
Design and optimisation of potent gp120-CD4 inhibitors
Thien-Duc Tran, Fiona M Adam, Frederick Calo, et al.
Cytotherapy
|
May 31, 2024
Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products
Bo Angela Wan, Lorenzo Lindo, Yasser Abou Mourad, et al.
Blood Advances
|
October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Mazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
European Journal of Medicinal Chemistry
|
November 19, 2024
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis
Henry Danahay, Martin Gosling, Roy Fox, et al.
Page
of 63
Search research articles
Search
Showing results (571-580 of 621) with videos related to
Sort By:
Page
of 63
Proceedings of the National Academy of Sciences of the United States of America
|
August 12, 2015
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch, Cynthia Tallant, Oleg Fedorov, et al.
Blood
|
September 20, 2017
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A Hay, Laïla-Aïcha Hanafi, Daniel Li, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 23, 2007
Aminopyrrolidineamide inhibitors of site-1 protease
Bruce A Hay, Barbara Abrams, Allice Y Zumbrunn, et al.
Blood Advances
|
November 20, 2019
Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy
Joshua A Hill, Elizabeth M Krantz, Kevin A Hay, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 26, 2008
Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals
Julie L Hawkins, Michael D Robbins, Laurie C Warren, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 20, 2004
2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors
Stephen M Courtney, Philip A Hay, Richard T Buck, et al.
Bioorganic & Medicinal Chemistry Letters
|
July 28, 2009
Design and optimisation of potent gp120-CD4 inhibitors
Thien-Duc Tran, Fiona M Adam, Frederick Calo, et al.
Cytotherapy
|
May 31, 2024
Outcomes with allogeneic stem cell transplant using cryopreserved versus fresh hematopoietic progenitor cell products
Bo Angela Wan, Lorenzo Lindo, Yasser Abou Mourad, et al.
Blood Advances
|
October 25, 2019
Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy
Mazyar Shadman, Jordan Gauthier, Kevin A Hay, et al.
European Journal of Medicinal Chemistry
|
November 19, 2024
Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis
Henry Danahay, Martin Gosling, Roy Fox, et al.
Page
of 63